Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;79(1):209-217.
doi: 10.1016/j.jhep.2023.01.026. Epub 2023 Feb 4.

Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties

Alina M Allen  1 , Jeffrey V Lazarus  2 , Zobair M Younossi  3
Affiliations
Review

Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties

Alina M Allen et al. J Hepatol. 2023 Jul.

Abstract

Left unaddressed, non-alcoholic fatty liver disease (NAFLD) will continue to have substantial health, economic and social implications. To address the challenge, a paradigm shift is needed in the way NAFLD is conceptualised. Concerted, collaborative action across medical specialities, industry sectors and governments will be vital in tackling this public health threat. To drive this change, in this review, we present data on the current global healthcare and socioeconomic costs of NAFLD and highlight priority actions. The estimated healthcare costs of patients with NAFLD are nearly twice as high as their age-matched counterparts without the disease and are highest in those with advanced fibrosis and end-stage liver disease. NAFLD is accountable for the highest increase in DALYs (disability-adjusted life years) among all liver diseases globally. NAFLD and non-alcoholic steatohepatitis (NASH)-specific drug therapies are not yet available and there is considerable uncertainty regarding cost, optimal length of treatment, and their impact on liver-related outcomes and mortality. Among the currently available bariatric procedures, sleeve gastrectomy is reported to be the most cost-effective for NASH resolution. Gastric bypass remains very expensive, while data on bariatric endoscopy are limited. Lastly, we propose a global NAFLD/NASH investment framework to guide the development of achievable yet ambitious country-specific targets and strategic actions to optimise resource allocation and reduce the prevalence of NAFLD and NASH. Its focus on high-level inputs will be critical to enabling a political and financial environment that supports clinical-level implementation of NAFLD prevention, treatment and care efforts, across all settings.

Keywords: Burden; Healthcare costs; MAFLD; Socioeconomic costs; Steatotic liver disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Global NAFLD prevalence (1998–2022)
Figure 2.
Figure 2.
Increasing NAFLD prevalence over time
Figure 3.
Figure 3.
Proposal for a global NAFLD/NASH investment framework
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paik JM, Golabi P, Younossi Y, Mishra A Younossi ZM Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology 2020;72:1605–1616. - PubMed
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–54.e1–9; quiz e39–40. - PMC - PubMed
    1. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N et al. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol 2018;113:1649–1659. - PMC - PubMed
    1. Younossi ZM, Stepanova M, Ong J, Trimble G, AlQhatani S, Younossi I et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580–589.e5. - PubMed
    1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel_Rahman O et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5:1749–1768. - PMC - PubMed

Publication types

MeSH terms